Healthcare Industry News:  macular edema 

Devices Ophthalmology Venture Capital

 News Release - April 21, 2009

iScience Interventional, Inc. Closes $20.5 million Series F Financing

MENLO PARK, Calif.--(HSMN NewsFeed)--iScience Interventional, Inc., the developer of a novel microcatheter technology used in the treatment of a wide range of sight threatening diseases, including glaucoma and Age-related Macular Degeneration (AMD), today announced the closing of a Series “F” financing raising $20.5 million. Affinity Capital Management led the round with Johnson & Johnson Development Corp., L Capital Partners, and Clarian Health Ventures participating as first time investors. Existing investors, Prism VentureWorks, Three Arch Ventures, DeNovo Ventures and Asset Management also participated in the financing. Piper Jaffray & Company served as the placement agent for this transaction.

“The treatment paradigms for many significant diseases of the eye such as glaucoma, AMD, and diabetic macular edema are in the midst of a revolutionary change. The need for access to the specific locations within the eye where these diseases occur is paramount to improving patient outcomes. The iTrack™ microcatheter uniquely provides such site-specific access, thus enabling an exciting new generation of medical therapies.” stated Michael F. Nash, President and CEO of iScience Interventional, Inc. “We believe that these sight specific treatments will represent a dramatic step forward in patient care, while providing a valuable benefit to both private healthcare providers and public healthcare systems.”

Glaucoma and retinal diseases represent the two most underserved clinical needs within ophthalmology. The Company has received FDA 510k clearance and CE Mark for the iTrack Canaloplasty Microcatheter™, which is used by glaucoma specialists for lowering intraocular pressure in patients with open angle glaucoma. Additionally, clinical studies are currently in progress in Europe to evaluate microcatheter-based delivery of drugs for the treatment of wet-AMD in patients non-responsive to current intravitreal therapies. The interim results of these studies are expected to be published later this year.

About iScience Interventional, Inc.

iScience Interventional, Inc. is based in Menlo Park, CA, and is the leader in the development of innovative microcatheter platforms that enable specific treatment of ocular disease. The iScience iTrack Canaloplasty Microcatheter™ platform used to treat open-angle glaucoma is commercially available in the United States, Canada and Europe. Clinical evaluation of the iCATH™ platform for the treatment of wet-AMD is currently underway at selected sites in Europe. For more information about the Company, please visit their Web site at

About Affinity Capital Management

Affinity Capital Management is a venture capital firm that invests in innovative and visionary companies and entrepreneurs to create groundbreaking improvements in health care. Based in Minneapolis, Minnesota, a center of ongoing health care innovation, Affinity has managed over $160 million since its inception in 1993. Affinity is currently investing its fifth fund, Affinity Capital V. For more information on Affinity Capital Management, please visit their website at

For additional information on investors in iScience Interventional, please visit:

L Capital Partners at

Clarian Health Ventures at

Three Arch Partners at

Prism VentureWorks at

De Novo Ventures at

Asset Management Partners at

Pacific Horizon Ventures at

For more information on Piper Jaffray & Company, please visit:

Source: iScience Interventional

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.